Literature DB >> 19339951

How HIV changes its tropism: evolution and adaptation?

Donald E Mosier1.   

Abstract

PURPOSE OF REVIEW: To present recent information on the evolution of coreceptor use from CCR5 alone to CCR5 and CXCR4, the impact CCR5 inhibitors have on this process, and new insights into HIV-1 binding to CD4 and CCR5. RECENT
FINDINGS: The findings that are summarized include resistance to CCR5 inhibitors, genotypic predictors of coreceptor use, the link between coreceptor use and cell tropism, and new data on CCR5 structure and function.
SUMMARY: Resistance to CCR5 inhibitors is uncommon, and frequently involves selection of minor populations of R5X4 virus. Genotypic predictors of coreceptor use need to take into account the entire envelope sequence, not just V3. Genetic polymorphisms in humans that affect CCR5 or chemokines that bind CCR5 affect not only virus entry but also immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339951      PMCID: PMC2697388          DOI: 10.1097/COH.0b013e3283223d61

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  58 in total

1.  Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

Authors:  Robert A Ogert; Lisa Wojcik; Catherine Buontempo; Lei Ba; Peter Buontempo; Robert Ralston; Julie Strizki; John A Howe
Journal:  Virology       Date:  2008-01-10       Impact factor: 3.616

2.  CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals.

Authors:  Andrew J Low; David Marchant; Chanson J Brumme; Zabrina L Brumme; Winnie Dong; Tobias Sing; Robert S Hogg; Julio S G Montaner; Vikram Gill; Peter K Cheung; P Richard Harrigan
Journal:  AIDS Res Hum Retroviruses       Date:  2008-02       Impact factor: 2.205

3.  Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus.

Authors:  Younong Xu; Haiying Zhu; Carrie K Wilcox; Angélique van't Wout; Thomas Andrus; Nicholas Llewellyn; Leonidas Stamatatos; James I Mullins; Lawrence Corey; Tuofu Zhu
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

4.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

5.  Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa.

Authors:  Bridgette J Connell; Katherine Michler; Alexio Capovilla; Willem D F Venter; Wendy S Stevens; Maria A Papathanasopoulos
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

6.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Authors:  Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440

7.  Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.

Authors:  Carolina Garrido; Vanessa Roulet; Natalia Chueca; Eva Poveda; Antonio Aguilera; Katharina Skrabal; Natalia Zahonero; Silvia Carlos; Federico García; Jean Louis Faudon; Vincent Soriano; Carmen de Mendoza
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

8.  Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.

Authors:  Paul J Peters; Maria J Duenas-Decamp; W Matthew Sullivan; Richard Brown; Chiambah Ankghuambom; Katherine Luzuriaga; James Robinson; Dennis R Burton; Jeanne Bell; Peter Simmonds; Jonathan Ball; Paul R Clapham
Journal:  Retrovirology       Date:  2008-01-18       Impact factor: 4.602

9.  Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

Authors:  Jasminka Sterjovski; Melissa J Churchill; Anne Ellett; Lachlan R Gray; Michael J Roche; Rebecca L Dunfee; Damian F J Purcell; Nitin Saksena; Bin Wang; Secondo Sonza; Steven L Wesselingh; Ingrid Karlsson; Eva-Maria Fenyo; Dana Gabuzda; Anthony L Cunningham; Paul R Gorry
Journal:  Retrovirology       Date:  2007-12-12       Impact factor: 4.602

10.  Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.

Authors:  Ahidjo Ayouba; Claude Cannou; Marie-Thérèse Nugeyre; Françoise Barré-Sinoussi; Elisabeth Menu
Journal:  Retrovirology       Date:  2008-03-31       Impact factor: 4.602

View more
  22 in total

1.  Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B.

Authors:  Laura Monno; Annalisa Saracino; Luigia Scudeller; Grazia Punzi; Gaetano Brindicci; Maurantonio Altamura; Antonella Lagioia; Nicoletta Ladisa; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 2.  CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Authors:  Michelle B Kim; Kyle E Giesler; Yesim A Tahirovic; Valarie M Truax; Dennis C Liotta; Lawrence J Wilson
Journal:  Expert Opin Investig Drugs       Date:  2016-12       Impact factor: 6.206

3.  Copy Number Variation within Human β-Defensin Gene Cluster Influences Progression to AIDS in the Multicenter AIDS Cohort Study.

Authors:  Rajeev K Mehlotra; Jean-Eudes Dazard; Bangan John; Peter A Zimmerman; Aaron Weinberg; Richard J Jurevic
Journal:  J AIDS Clin Res       Date:  2012

4.  Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.

Authors:  Timothy J Henrich; Emily Hanhauser; Zixin Hu; Hans-Jürgen Stellbrink; Christian Noah; Jeffrey N Martin; Steven G Deeks; Daniel R Kuritzkes; Florencia Pereyra
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

Review 5.  Two-stepping through time: mammals and viruses.

Authors:  Nicholas R Meyerson; Sara L Sawyer
Journal:  Trends Microbiol       Date:  2011-04-30       Impact factor: 17.079

6.  Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.

Authors:  Maria José Duenas-Decamp; Paul J Peters; Alexander Repik; Thomas Musich; Maria Paz Gonzalez-Perez; Catherine Caron; Richard Brown; Jonathan Ball; Paul R Clapham
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

7.  V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.

Authors:  Ellen Wu; Yueqi Du; Xiang Gao; Jie Zhang; John Martin; Makedonka Mitreva; Lee Ratner
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

8.  One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.

Authors:  Paul W Denton; Florence Othieno; Francisco Martinez-Torres; Wei Zou; John F Krisko; Elisa Fleming; Sima Zein; Daniel A Powell; Angela Wahl; Youn Tae Kwak; Brett D Welch; Michael S Kay; Deborah A Payne; Philippe Gallay; Ettore Appella; Jacob D Estes; Min Lu; J Victor Garcia
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

9.  CCR5: From Natural Resistance to a New Anti-HIV Strategy.

Authors:  Lucia Lopalco
Journal:  Viruses       Date:  2010-02-05       Impact factor: 5.818

Review 10.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.